A group of scientists from the University of the Philippines (UP) Diliman has identified potential biomarkers for lung cancer ...

Lineage Cell Therapeutics, Inc.’s LCTX share price has dipped by 5.08%, which has investors questioning if this is right time ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced HER2-mutant non-small cell lung cancer – particularly those with specific HER2 ...

Zongertinib shows promise for treating HER2-mutant non–small cell lung cancer (NSCLC), with significant activity against brain metastases and low interstitial lung disease risk, explains John Heymach, ...

The HER2-targeted therapy zongertinib demonstrated clinical benefits for previously treated patients with advanced ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

Limited’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Scientists have discovered that a rare immune cell type in the lungs, called NAMs, plays a crucial role in surviving COVID-19 ...

Summit Therapeutics' partner Akeso received FDA approval for penpulimab-kcqx in NPC, while ivonescimab showed strong data in ...

Cindy was a healthy, 35-year-old woman with no symptoms of cancer when she joined the American Lung Association’s Lung Health Cohort Study.